Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 635-643

  Barten, D M ^a   Guss, V L ^a   Corsa, J A ^a   Loo, A ^a,b   Hansel, S B ^a   Zheng, M ^a   Munoz, B ^c   Srinivasan, K ^d   Wang, B ^c   Robertson, B J ^a   Polson, C T ^a   Wang, J ^a   Roberts, S B ^a   Hendrick, J P ^a,e   Anderson, J J ^c,f   Loy, J K ^a,g   Denton, R ^a   Verdoorn, T A ^a,h   Smith, D W ^a   Felsenstein, K M ^a,i  

^a BRISTOL MYERS SQUIBB   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Neurogenetics Inc   (United States)

^e Intra Cellular Therapies Inc   (United States)

^f Cypress Bioscience Inc   (United States)

^g PFIZER INC   (United States)

^h Algos Therapeutics Inc   (United States)

ⁱ Johnson and Johnson PRD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [[(4 CHLOROPHENYL)SULFONYL](2,5 DIFLUOROPHENYL)AMINO]ETHYL] 5 FLUOROBENZENEPROPANOIC ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BMS 299897; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL MATURATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GOBLET CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; THYMOCYTE; TRANSGENIC MOUSE;

AGING; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BLOTTING, WESTERN; BRAIN CHEMISTRY; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOPRECIPITATION; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEASE INHIBITORS; RECEPTORS, NOTCH; SENILE PLAQUES; T-LYMPHOCYTES;

EID: 19944430290     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.075408     Document Type: Article

References (42)

1. Allman D, Aster JC, and Pear WS (2002) Notch signaling in hematopoiesis and early lymphocyte development. Immunol Rev 187:75-86.
2. Brittan M and Wright NA (2002) Gastrointestinal stem cells. J Pathol 197:492-509.
3. Buxbaum JD, Thinakaran G, Koliatsos V, O'Callahan J, Slunt HH, Price DL, and Sisodia SS (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J Neurosci 18:9629-9637.
4. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, and Wong PC (2001) BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4:233-234.
5. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, and Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8:1390-1397.
6. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676.
7. Chodobski A and Szmydynger-Chodobska J (2001) Choroid plexus: target for polypeptides and site of their synthesis. Microsc Res Tech 52:65-82.
8. Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JB, Nissen JS, Bales KR, Paul SM, et al. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 23:8844-8853.
9. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907-913.
10. DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, and Holtzman DM (2002) Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 81:229-236.
11. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, et al. (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76:173-181.
12. Geling A, Steiner H, Willem M, Bally-Cuif L, and Haass C (2002) A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 3:688-694.
13. Germain RN (2002) T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol 2:309-322.
14. Ghersi-Egea JF and Strazielle N (2001) Brain drug delivery, drug metabolism and multidrug resistance at the choroid plexus. Microsc Res Tech 52:83-88.
15. Haugabook SJ, Le T, Yager D, Zenk B, Healy BM, Eckman EA, Prada C, Younkin L, Murphy P, Pinnix I, et al. (2001) Reduction of Abeta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidylinositol kinase inhibitor wortmannin. FASEB J 15:16-18.
16. Hone E, Martins IJ, Fonte J, and Martins RN (2003) Apolipoprotein E influences amyloid-beta clearance from the murine periphery. J Alzheimers Dis 5:1-8.
17. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G (1996) Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science (Wash DC) 274:99-102.
18. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, and Gordon MN (2002) Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254.
19. Josien H (2002) Recent advances in the development of gamma-secretase inhibitors. Curr Opin Drug Discov Dev 5:513-525.
20. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, and Younkin SG (2001) Age-dependent changes in brain, CSF and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21:372-381.
21. Klafki HW, Wiltfang J, and Staufenbiel M (1996) Electrophoretic separation of betaA4 peptides (1-40) and (1-42). Anal Biochem 237:24-29.
22. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, and Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271:4077-4081.
23. Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, and Merchant KM (2003) The gamma-secretase inhibitor N-[N-(S,5-difluorophenacetyl)-L-alanyl] -S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305:864-871.
24. Lanz TA, Hosley JD, Adams WJ, and Merchant KM (2004) Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo [b,d] azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 309:49-55.
25. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, et al. (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
26. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, et al. (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29-33.
27. Micchelli CA, Esler WP, Kimberly WT, Jack C, Berezovska O, Kornilova A, Hyman BT, Perrimon N, and Wolfe MS (2003) Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 17:79-81.
28. Mizutani T, Taniguchi Y, Aoki T, Hashimoto N, and Honjo T (2001) Conservation of the biochemical mechanisms of signal transduction among mammalial Notch family members. Proc Natl Acad Sci USA 98:9026-9031.
29. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, Dewachter I, Banks WA, Van Leuven F, and Soto C (2002) Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J 16:860-862.
30. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, et al. (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8:890-899.
31. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, Reaume AG, Greenberg BD, Siman R, and Scott RW (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18:1743-1752.
32. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (Lond) 400:173-177.
33. Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR, Gao H, Higgins MA, May PC, and Ryan TP (2003) Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278:46107-46116.
34. Selkoe D and Kopan R (2003) Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 26:565-597.
35. Shibata M, Yamada S, Kumar SB, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, et al. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Investig 106:1489-1499.
36. Smith DW, Munoz B, Srinivasan K, Bergstrom CP, Chaturvedula PV, Deshpande MS, Keavy DJ, Lau W, Yu, Parker MF, et al. (2000) Novel sulfonamide compounds and uses thereof, in US0004560, Merck & Co., Inc.; Bristol-Myers Squibb, US.
37. Tian G, Sobotka-Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, Edwards PD, Scott CD, and Greenberg BD (2002) Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides and benzodiazepines. J Biol Chem 277:31499-31505.
38. Weller RO (1998) Pathology of cerebrospinal fluid and interstitial fluid of the CNS: significance for Alzheimer disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 57:885-894.
39. Wilson CA, Doms RW, and Lee VM (2003) Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. J Neurosci Res 74:361-369.
40. Wolfe MS (2001) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem 44:2039-2060.
41. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, et al. (2004) Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882.
42. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, and Landreth G (2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509.